Crucell to move Dukoral production out of Sweden
Leiden, Netherlands-based Crucell intends to move Dukoral and rCTB bulk production, formulation and fill/finish activities from Sweden to sites in other countries as a cost-cutting measure. Nordic sales and customer service and distribution activities remain unaffected. The company expects the move to result in additional cost savings extending beyond 2011.
The formulation, filling and packaging of Dukoral in Sweden will stop during 2011 and will move to Spain; the bulk production of Dukoral and rCTB will halt in 2012, relocating to Switzerland; Nordic sales and customer service and distribution activities will continue to operate from Solna in Sweden; and research activities will be closed and concentrated in Leiden before year-end 2008.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze